Stutter, tic and the Gilles de la Tourette syndrome have many features in common. Haloperidol has been found of value in the treatment of the last-named syndrome (1) and also of tic (2). Our study was intended to evaluate its use, combined with orphenadrine, in stutterers. We used it both with and without speech therapy, as shown in Table I. The trial was controlled, and double blind. Our 36 patients, aged 15 to 60, were of both sexes and neither psychotic nor subnormal. They were not on other therapy. They were randomly divided by an independent third party equally into the following groups, and treated as indicated.